Adriana M Hung1,2, Chutatip Limkunakul3, Jenny S Placido4, Edward D Siew3, Charles D Ellis3, Ayumi Shintani5, Talat Alp Ikizler6,3. 1. Clinical Science Research & Development Veterans Administration, TVHS, Nashville, TN, USA. adriana.hung@vanderbilt.edu. 2. Division of Nephrology, Vanderbilt University Medical Center, 1161 21st Ave. South, S-3223 MCN, Nashville, TN, 37232-2372, USA. adriana.hung@vanderbilt.edu. 3. Division of Nephrology, Vanderbilt University Medical Center, 1161 21st Ave. South, S-3223 MCN, Nashville, TN, 37232-2372, USA. 4. Universidad San Juan Bautista, Caguas, PR, USA. 5. Biostatistics, Vanderbilt University, Nashville, TN, USA. 6. Clinical Science Research & Development Veterans Administration, TVHS, Nashville, TN, USA.
Abstract
BACKGROUND: Adiponectin, an adipose tissue derived hormone, is known to have insulin-sensitizing, anti-inflammatory, and anti-atherogenic properties in the general population. Adiponectin secretion is suppressed by systemic inflammation, a highly prevalent condition in maintenance hemodialysis (MHD) patients. We evaluated whether short-term administration of interleukin 1 receptor antagonist (IL-1ra) improves adiponectin levels and insulin sensitivity in MHD patients. METHODS: Ad hoc analysis was performed on a pilot randomized placebo-controlled trial of the administration of IL-1ra in chronically inflamed MHD patients. Twenty-two patients were randomly assigned to receive 100 mg of IL-1ra or placebo (1:1) for 4 weeks, and 14 completed the trial. ANCOVA was used to compare percent change from baseline to 4 weeks. The primary outcome was percent change in adiponectin and the secondary outcomes were changes in leptin, homeostatic model assessment of insulin resistance (HOMA-IR) and the leptin-to-adiponectin ratio (LAR). RESULTS:Patients' mean age was 49 ± 13 years, and 71 % were males. At baseline, the median values for adiponectin, leptin, LAR and HOMA-IR were 11.5 μg/ml [interquartile range (IQR) 9, 28.5], 17.8 ng/ml (3.9, 50.0), 2.20 (0.13, 3.98), and 2.8 (2.0, 3.6), respectively. IL-1ra administration resulted in a mean percent increase in serum adiponectin of 22 % vs. 14 % decrease in the placebo arm (p = 0.003). Leptin, LAR or HOMA-IR levels did not change in either arm. CONCLUSIONS: Short-term administration of IL-1ra significantly increased adiponectin levels among prevalent MHD patients. The intervention did not impact insulin sensitivity parameters. Studies of longer duration and larger sample size are needed to further evaluate the potential effect of anti-inflammatory interventions on metabolic markers and insulin sensitivity in MHD patients.
RCT Entities:
BACKGROUND:Adiponectin, an adipose tissue derived hormone, is known to have insulin-sensitizing, anti-inflammatory, and anti-atherogenic properties in the general population. Adiponectin secretion is suppressed by systemic inflammation, a highly prevalent condition in maintenance hemodialysis (MHD) patients. We evaluated whether short-term administration of interleukin 1 receptor antagonist (IL-1ra) improves adiponectin levels and insulin sensitivity in MHD patients. METHODS: Ad hoc analysis was performed on a pilot randomized placebo-controlled trial of the administration of IL-1ra in chronically inflamed MHD patients. Twenty-two patients were randomly assigned to receive 100 mg of IL-1ra or placebo (1:1) for 4 weeks, and 14 completed the trial. ANCOVA was used to compare percent change from baseline to 4 weeks. The primary outcome was percent change in adiponectin and the secondary outcomes were changes in leptin, homeostatic model assessment of insulin resistance (HOMA-IR) and the leptin-to-adiponectin ratio (LAR). RESULTS:Patients' mean age was 49 ± 13 years, and 71 % were males. At baseline, the median values for adiponectin, leptin, LAR and HOMA-IR were 11.5 μg/ml [interquartile range (IQR) 9, 28.5], 17.8 ng/ml (3.9, 50.0), 2.20 (0.13, 3.98), and 2.8 (2.0, 3.6), respectively. IL-1ra administration resulted in a mean percent increase in serum adiponectin of 22 % vs. 14 % decrease in the placebo arm (p = 0.003). Leptin, LAR or HOMA-IR levels did not change in either arm. CONCLUSIONS: Short-term administration of IL-1ra significantly increased adiponectin levels among prevalent MHD patients. The intervention did not impact insulin sensitivity parameters. Studies of longer duration and larger sample size are needed to further evaluate the potential effect of anti-inflammatory interventions on metabolic markers and insulin sensitivity in MHD patients.
Authors: Noël J M Cano; Denis Fouque; Hubert Roth; Michel Aparicio; Raymond Azar; Bernard Canaud; Philippe Chauveau; Christian Combe; Maurice Laville; Xavier M Leverve Journal: J Am Soc Nephrol Date: 2007-07-26 Impact factor: 10.121
Authors: C Lagathu; L Yvan-Charvet; J-P Bastard; M Maachi; A Quignard-Boulangé; J Capeau; M Caron Journal: Diabetologia Date: 2006-07-25 Impact factor: 10.122
Authors: Aina S Lihn; Jens M Bruun; Gengsheng He; Steen B Pedersen; Peter F Jensen; Bjørn Richelsen Journal: Mol Cell Endocrinol Date: 2004-04-30 Impact factor: 4.102
Authors: Adriana M Hung; Yohei Tsuchida; Kristen L Nowak; Sudipa Sarkar; Michel Chonchol; Victoria Whitfield; Natjalie Salas; Anna Dikalova; Patricia G Yancey; Jiansheng Huang; MacRae F Linton; T Alp Ikizler; Valentina Kon Journal: Clin J Am Soc Nephrol Date: 2019-04-23 Impact factor: 8.237
Authors: Kirsten L Johansen; Lorien S Dalrymple; Cynthia Delgado; Glenn M Chertow; Mark R Segal; Janet Chiang; Barbara Grimes; George A Kaysen Journal: Clin J Am Soc Nephrol Date: 2017-06-02 Impact factor: 8.237
Authors: R Kaseda; Y Tsuchida; J L Gamboa; J Zhong; L Zhang; H Yang; A Dikalova; A Bian; S Davies; A F Fogo; M F Linton; N J Brown; T A Ikizler; V Kon Journal: Nutr Metab Cardiovasc Dis Date: 2018-03-08 Impact factor: 4.222